StreetInsider.com News Articles

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 03:00:00 +0000

REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close.

The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).

To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration
To participate in the

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Wed, 04 Mar 2026 03:00:00 +0000

The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).

To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration
To participate in the

Form 6-K Alvotech For: Feb 27

Fri, 27 Feb 2026 07:12:00 +0000

si-local-file:///var/storage/secattach/20260227/26075686.html

Form 6-K Alvotech For: Feb 27

Fri, 27 Feb 2026 07:12:00 +0000

si-local-file:///var/storage/secattach/20260227/26075686.html

Alvotech issues 12.5 million shares to subsidiary for $65 million

Wed, 11 Feb 2026 11:00:36 +0000

Alvotech (NASDAQ: ALVO) issued 12.5 million ordinary shares to its subsidiary Alvotech Manco ehf. for $5.2 per share, totaling $65 million, according to a company statement released February 11.

The transaction increased Alvotech's total issued shares from 334,038,147 to 346,538,147. The subsidiary now holds 16,254,005 shares, representing 4.7% of issued shares. These shares are treated as treasury shares without voting rights or dividend entitlement.

The number of outstanding shares remains unchanged at 330,284,142, as the newly issued shares are held as treasury stock.

Alvotech stated the share issuance is intended to replenish treasury shares used in a stock lending facility announced December 17,

Alvotech issues 12.5 million shares to subsidiary for $65 million

Wed, 11 Feb 2026 11:00:36 +0000

Alvotech (NASDAQ: ALVO) issued 12.5 million ordinary shares to its subsidiary Alvotech Manco ehf. for $5.2 per share, totaling $65 million, according to a company statement released February 11.

The number of outstanding shares remains unchanged at 330,284,142, as the newly issued shares are held as treasury stock.

Alvotech stated the share issuance is intended to replenish treasury shares used in a stock lending facility announced December 17,

Alvotech Announces Increase in Number of Own Shares

Wed, 11 Feb 2026 11:00:00 +0000

REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

Following the above-mentioned transaction,

Alvotech Announces Increase in Number of Own Shares

Wed, 11 Feb 2026 11:00:00 +0000

Following the above-mentioned transaction,

Form 6-K Alvotech For: Feb 05

Thu, 05 Feb 2026 07:00:00 +0000

si-local-file:///var/storage/secattach/20260205/25950346.html

Form 6-K Alvotech For: Feb 05

Thu, 05 Feb 2026 07:00:00 +0000

si-local-file:///var/storage/secattach/20260205/25950346.html

Alvotech reports positive results for Entyvio biosimilar study

Thu, 05 Feb 2026 05:48:53 +0000

Alvotech (NASDAQ: ALVO) announced that its pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio, met all primary endpoints. The randomized, double-blind study compared AVT80 to Entyvio in healthy adult participants following a single 108 mg subcutaneous injection.

The study assessed pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio. According to the company, the results allow Alvotech to proceed toward regulatory submissions for the biosimilar candidate.

Alvotech is developing two proposed Entyvio biosimilars: AVT16 for intravenous administration and AVT80 for subcutaneous administration. The company stated that this study satisfies pharmacokinetic similarity demonstration for both administration routes and is considered pivotal

Alvotech reports positive results for Entyvio biosimilar study

Thu, 05 Feb 2026 05:48:53 +0000

Alvotech reports positive results for Entyvio biosimilar study

Thu, 05 Feb 2026 05:48:53 +0000

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Thu, 05 Feb 2026 03:00:00 +0000

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints

REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to Entyvio® (vedolizumab).

The PK study (AVT80-GL-P01), which compared AVT80 to Entyvio in healthy adult participants, met all its primary endpoints. This was a randomized, double-blind,

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Thu, 05 Feb 2026 03:00:00 +0000

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints

The PK study (AVT80-GL-P01), which compared AVT80 to Entyvio in healthy adult participants, met all its primary endpoints. This was a randomized, double-blind,